Tom Davies, a 20-year-old from Brighton, narrowly avoided a hospital admission after accidentally overdosing on a fake version of retatrutide ordered from a Chinese supplier on the recommendation of gym acquaintances. The unregulated compound left him suffering from severe nausea and prolonged diarrhoea for 72 hours after he miscalculated his intake and administered eight times the recommended dosage.
The Dangers of Unregulated Online Purchases
“It was horrendous,” Tom says of the experience, describing a sensation where his body felt under immense pressure and heavily bloated, likening it to having a 20kg weight dropped on his stomach. He admits that as the severe side effects persisted, he genuinely thought he would end up in A&E. Unofficial copycat retatrutide can sometimes be delivered in a state requiring reconstitution with sterile, bacteriostatic water, which calls for various calculations depending on the specific order.
Even after suffering through that scary first experience, Tom took time to research the proper dosages and chose to give his counterfeit retatrutide another chance despite the unpleasant side effects he had endured earlier. Following nine months of cyclical use, he reports that his desires for sugary items and fast food have completely disappeared.
Did you know? While drugs like semaglutide (sold as Ozempic and Wegovy) and tirzepatide (sold as Mounjaro) focus on only one or two hormone receptors, retatrutide will stand as the globe’s inaugural weight loss treatment to engage three if it receives approval, earning it the moniker the “triple G”.
Clinical Trial Oversight Versus DIY Dosing
Dr Nas Khattak, a research doctor based in Chester, has been screening patients for one of Eli Lilly’s Phase III clinical trials. He says those sourcing fake versions are in effect behaving as lab rats without any medical oversight. According to Dr Khattak, if users who buy it online become their own doctor, they’re taking a huge risk.
Legitimate clinical evaluations require rigorous protocols before participants are given the green light to start taking the real drug or a placebo. “We request their GP record, we make sure that they’re emotionally well. They’ll have suicide, self-harm, mental health assessments – and this is all done by doctors,” Dr Khattak explains, pointing out that practitioners subsequently review everything, including blood tests, to evaluate whether candidates are appropriate for participation.
Sharing similar safety apprehensions, pharmacist Shahid cautions that an illicit version of reta succeeding for a single individual offers no guarantee that it will “work for the next”.
How Retatrutide Works on the Body
Current anti-obesity medications available on the market—such as semaglutide (sold under the names Ozempic and Wegovy) and tirzepatide (sold as Mounjaro)—interact with merely one or two hormone receptors. Yet, pending approval, retatrutide is set to become the world’s very first weight loss medication interacting with three, inspiring its “triple G” label.
- GLP-1: This mechanism delays gastric emptying, signals satiety to the brain to suppress hunger, and assists in regulating blood glucose levels.
- GIP: This enhances insulin secretion and improves insulin sensitivity, and works alongside GLP-1 to help the body process nutrients and reduces hunger.
- Glucagon: It boosts resting energy expenditure so that the body expends a higher volume of calories, stimulates the breakdown of liver fat, and aids in shedding weight.
Frequently Asked Questions
What makes retatrutide different from Ozempic or Mounjaro?
Retatrutide targets three hormone receptors, whereas current market alternatives target just one or two.
Why are online copycat versions of weight loss drugs dangerous?
What safety checks are performed in official clinical trials?
Authorized trials involve GP record reviews, mental health assessments, and blood tests to determine patient suitability.
Join the Conversation: Have questions about the future of metabolic treatments or clinical trial safety? Leave a comment below or subscribe to our newsletter for regular updates on pharmaceutical advancements.
Related reading